Skip to main content
Amoy Diagnostics Co.,Ltd. logo

Amoy Diagnostics Co.,Ltd. — Investor Relations & Filings

Ticker · 300685 ISIN · CNE1000034D3 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,088 across all filing types
Latest filing 2023-04-21 Interim / Quarterly Rep…
Country CN China
Listing Shenzhen Stock Exchange 300685

About Amoy Diagnostics Co.,Ltd.

https://www.amoydx.com

Amoy Diagnostics Co., Ltd. specializes in the development and commercialization of molecular diagnostic products for precision oncology. The company provides a comprehensive portfolio of testing kits designed to identify genetic mutations and biomarkers essential for personalized cancer treatment. Its core technology platforms include the proprietary ADx-ARMS, Super-ARMS, and specialized Next-Generation Sequencing (NGS) solutions. AmoyDx focuses on companion diagnostics (CDx), collaborating extensively with global pharmaceutical companies to integrate diagnostic testing into clinical drug development and patient management. Key products cover a wide range of solid tumors, including lung, colorectal, and breast cancers, facilitating targeted therapy selection and monitoring. The company maintains rigorous quality standards, with numerous products receiving regulatory approvals for clinical use in multiple international markets.

Recent filings

Filing Released Lang Actions
2023年一季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled "厦门艾德生物医药科技股份有限公司 2023 年第一季度报告" which translates to "Xiamen Aide Biomedical Technology Co., Ltd. 2023 First Quarter Report." It contains detailed financial data including balance sheets, income statements, cash flow statements, and notes on financial metrics for the first quarter of 2023. The document explicitly states it is a quarterly report and mentions it is unaudited. The length of the document (12,594 characters) and the presence of comprehensive financial statements confirm it is a substantive financial report for a period shorter than a full fiscal year. Therefore, it fits the definition of an Interim / Quarterly Report (IR).
2023-04-21 Chinese
第三届监事会第十次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a formal announcement of the supervisory board meeting resolution approving the company's 2023 first quarter report. It states the meeting details, voting results, and confirms the report's compliance and accuracy. The document itself does not contain the full quarterly report or detailed financial data but rather the resolution and approval of that report. The length is short (619 characters), and it serves as an announcement of the approval of the quarterly report rather than the report itself. Therefore, it fits best under Regulatory Filings (RNS) as a formal compliance announcement rather than an Interim/Quarterly Report (IR).
2023-04-21 Chinese
独立董事述职报告（王恩华）
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Director 2022 Annual Work Report" from Xiamen Aide Biomedical Technology Co., Ltd. It details the independent director's attendance at board meetings, opinions on company matters, committee work, inspections, investor protection efforts, and training during the 2022 fiscal year. The content is a detailed report on the independent director's activities and responsibilities over the year, rather than an announcement or a brief summary. It does not contain financial statements or audit results but focuses on board/management oversight and governance activities. This fits best under the category of Board/Management Information (MANG), which covers announcements related to changes or reports from the company's board or senior management. The document length is 2249 characters, which is relatively short but contains substantive content about board activities rather than just an announcement of a report. Therefore, the classification is MANG with high confidence.
2023-04-14 Chinese
2022年度内部控制自我评价报告
Audit Report / Information Classification · 95% confidence The document is titled '2022 年度内部控制自我评价报告' which translates to '2022 Annual Internal Control Self-Evaluation Report'. It is issued by the company's board of directors and discusses the internal control evaluation for the fiscal year ending December 31, 2022. The content includes detailed descriptions of internal control environment, risk assessment, control activities, information systems, communication, and internal supervision. It also includes standards for identifying internal control deficiencies and the company's conclusions on the effectiveness of internal controls. The document is comprehensive and contains substantive information about the company's internal control evaluation, which is typically part of an Audit Report or Information related to internal controls rather than a full Annual Report. It is not a brief announcement or a certification letter but a detailed report on internal control evaluation. Therefore, the most appropriate classification is Audit Report / Information (AR).
2023-04-14 Chinese
独立董事述职报告（蔡宁）
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Director 2022 Annual Report" from a specific independent director of the company. It details the director's attendance at board and shareholder meetings, participation in committees, opinions on various company matters, and overall duties performed during the year 2022. The content focuses on the director's report on their responsibilities and activities rather than financial results or audit opinions. It is a formal report by a board member about their role and oversight activities, which fits the category of Board/Management Information (MANG). The document length is 2364 characters, which is relatively short but contains substantive content about management and board activities, not just an announcement or certification. Therefore, it is classified as MANG with high confidence.
2023-04-14 Chinese
关于2022年第三季度报告会计差错更正的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the correction of accounting errors in the company's 2022 third quarter report, specifically related to the cash flow statement. It details the nature of the corrections, the impact on financial data, and includes opinions from the board, supervisory board, and independent directors. The document references the 2022 third quarter report but does not contain the full financial statements or comprehensive financial data itself. It is a correction announcement related to a previously issued interim/quarterly report rather than the report itself. The document length is 4222 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this document should be classified as a Regulatory Filing (RNS) because it is a regulatory announcement about corrections to a financial report, not the report itself.
2023-04-14 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.